Skip to main content

Table 1 Age, sex and medication of the patients with psoriatic arthritis (PsA) at baseline (BL) and the 12- months (M12) and 24-months (M24) visits

From: Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up

 

BL

(N = 39)

M12

(N = 39)

M24

(N = 35)

Women, n(%)

 

25 (64.1)

21 (60.0)

Men, n(%)

 

14 (35.9)

14 (40.0)

Age, years (IQR)

 

56 (49–63)

59 (51–56)

NSAIDs, n (%)

27 (69.2)

25 (64.1)

21 (60.0)

TNFi all, n (%)

15 (38.5)

16 (41.0)

14 (40.0)

TNFi in monotherapy

4 (10.3)

4 (10.3)

3 (8.6)

TNFi + csDMARD

11 (28.2)

12 (30.7)

11 (31.4)

Ustekinumab monotherapy, n (%)

1 (2.6)

0

0

Secukinumab monotherapy, n (%)

0

1 (2.6)

2 (5.7)

csDMARD without biologic, n (%)

17 (43.6)

16 (41.0)

14 (40.0)

Methotrexate

11 (28.2)

11 (28.3)

10 (28.6)

Sulfasalazine

2 (5.1)

1 (2.6)

1 (2.9)

Apremilast

1 (2.6)

1 (2.6)

2 (5.7)

Methotrexate + Sulfasalazine

3 (7.7)

3 (7.7)

1 (2.9)

Prednisolone, n (%)

3 (7.7)

2 (5.1)

2 (5.7)

Anti-hypertensives, n (%)

17 (43.6)

14 (35.9)

14 (40.0)

Lipid lowering therapy, n (%)

6 (15.4)

5 (12.8)

5 (14.3)

Oral anti-diabetics, n (%)

1 (2.6)

2 (5.1)

2 (5.7)

Allopurinol, n (%)

2 (5.1)

2 (5.1)

2 (5.7)

  1. csDMARD = conventional synthetic Disease Modifying Anti-Rheumatic Drug, IQR = inter-quartile range, NSAID = non-steroidal anti-inflammatory drug, TNFi = tumor necrosis factor inhibitor